Dr. Zhang on the Importance of Adjuvant Clinical Trials in RCC

Tian Zhang, MD
Published: Wednesday, Jan 03, 2018



Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the importance of clinical trials in the adjuvant setting of renal cell carcinoma (RCC).

Although the utility of adjuvant therapy in the treatment of RCC is still contested, Zhang says that participation in clinical trials is beneficial.

Adjuvant therapy may delay time to disease recurrence, and in a setting where there is no standard of care, Zhang encourages community urologists and primary care physicians to recommend their patients to clinical trials of adjuvant therapy.
 


Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the importance of clinical trials in the adjuvant setting of renal cell carcinoma (RCC).

Although the utility of adjuvant therapy in the treatment of RCC is still contested, Zhang says that participation in clinical trials is beneficial.

Adjuvant therapy may delay time to disease recurrence, and in a setting where there is no standard of care, Zhang encourages community urologists and primary care physicians to recommend their patients to clinical trials of adjuvant therapy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x